INT94862

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.20
First Reported 2001
Last Reported 2010
Negated 1
Speculated 0
Reported most in Body
Documents 10
Total Number 10
Disease Relevance 4.23
Pain Relevance 5.18

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (Pde5a) signal transduction (Pde5a)
Anatomy Link Frequency
dorsal root ganglia 4
myocytes 2
Pde5a (Rattus norvegicus)
Pain Link Frequency Relevance Heat
amygdala 147 100.00 Very High Very High Very High
bradykinin 3 99.98 Very High Very High Very High
qutenza 6 99.70 Very High Very High Very High
analgesia 2 99.52 Very High Very High Very High
dorsal root ganglion 10 99.18 Very High Very High Very High
antinociception 43 98.64 Very High Very High Very High
Hyperalgesia 26 98.62 Very High Very High Very High
gABA 33 96.40 Very High Very High Very High
Neuropathic pain 64 95.80 Very High Very High Very High
Analgesic 8 93.04 High High
Disease Link Frequency Relevance Heat
Ganglion Cysts 13 99.18 Very High Very High Very High
Hyperalgesia 30 98.62 Very High Very High Very High
Anxiety Disorder 76 97.76 Very High Very High Very High
Nociception 15 97.04 Very High Very High Very High
Neuropathic Pain 100 95.80 Very High Very High Very High
INFLAMMATION 45 89.36 High High
Increased Venous Pressure Under Development 12 89.12 High High
Pain 33 80.76 Quite High
Disease 12 72.32 Quite High
Injury 14 71.84 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Guanylyl cyclase catalyzes the formation of cGMP from GTP, leading to the synthesis of cGMP, whereas cGMP-specific phosphodiesterase catalyzes the hydrolysis of cGMP to GMP, thereby ending signal transduction (5).
Positive_regulation (leading) of Gene_expression (synthesis) of cGMP
1) Confidence 0.20 Published 2008 Journal Journal of Korean Medical Science Section Body Doc Link PMC2610640 Disease Relevance 0.53 Pain Relevance 0.53
PDE4 is not inhibited by cGMP and thus originally PDE3 was called cGMP-inhibited PDE to distinguish it from PDE4. cGMP inhibition of PDE3 may be physiologically relevant to the elevation of cAMP levels in a variety of cells including human myocytes, where nitric oxide induced relaxation may be mediated by activation of guanylyl cyclase, elevation of intracellular cGMP levels and inhibition of PDE3 leading to elevated cAMP levels (Kirstein et al 1995).
Positive_regulation (activation) of Gene_expression (elevation) of cGMP in myocytes
2) Confidence 0.13 Published 2008 Journal International Journal of Chronic Obstructive Pulmonary Disease Section Body Doc Link PMC2650605 Disease Relevance 0.19 Pain Relevance 0.03
The inhibition of phosphodiesterase 5 produces an antinociception through the increase of cyclic guanosine monophosphate (cGMP), and increasing cGMP levels enhance the release of ?
Positive_regulation (increasing) of Gene_expression (levels) of cGMP associated with antinociception
3) Confidence 0.12 Published 2010 Journal Yonsei Medical Journal Section Abstract Doc Link PMC2799976 Disease Relevance 0.36 Pain Relevance 0.49
Guanylyl cyclase catalyzes the formation of cyclic guanosine monophosphate (cGMP) from GTP, leading to the synthesis of cGMP, whereas cGMP-specific phosphodiesterase catalyzes the hydrolysis of cGMP to GMP.2 Accordingly, intracellular cGMP concentrations are regulated by the action of guanylyl cyclase and the rate of degradation by cGMP-specific phosphodiesterase.6,7
Positive_regulation (whereas) of Gene_expression (synthesis) of cGMP
4) Confidence 0.12 Published 2010 Journal Yonsei Medical Journal Section Body Doc Link PMC2799976 Disease Relevance 1.14 Pain Relevance 1.41
It has been suggested that cGMP is involved in antinociception.8 In line with this observation, dibutyryl-cGMP and 8-bromo-cGMP showed antinociception in a modification of the Randall-Selitto hyperalgesia model and in a neuropathic pain model, respectively.7,9 Furthermore, sildenafil, a phosphodiesterase 5 inhibitor, caused antinociception in carrageenan-induced hyperalgesia, the writhing test and the formalin test.10-14 In a previous study, increasing cGMP levels with the phosphodiesterase inhibitor zaprinast enhanced the ?
Positive_regulation (increasing) of Gene_expression (levels) of cGMP associated with antinociception, hyperalgesia and neuropathic pain
5) Confidence 0.12 Published 2010 Journal Yonsei Medical Journal Section Body Doc Link PMC2799976 Disease Relevance 0.69 Pain Relevance 1.31
Further, this enhancement in pre- and postsynaptic protein expression in the LA following intra-LA infusion of 8-Br-cGMP was not observed in naïve animals that did not receive fear conditioning (Figure 4j,l).
Positive_regulation (enhancement) of Gene_expression (expression) of cGMP associated with anxiety disorder and amygdala
6) Confidence 0.06 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2888610 Disease Relevance 0.15 Pain Relevance 0.39
These observations lead to the suggestion that NO acts in a paracrine fashion when stimulating the synthesis of cGMP and may not be synthesized at all sites containing nNOS.
Neg (not) Positive_regulation (stimulating) of Gene_expression (synthesis) of cGMP
7) Confidence 0.05 Published 2001 Journal Nitric Oxide Section Abstract Doc Link 11292360 Disease Relevance 0.25 Pain Relevance 0.17
In both dissociated dorsal root ganglion (DRG) cultures and in acutely isolated, but intact, DRG, treatment with capsaicin or bradykinin caused cGMP synthesis, which could be blocked by NOS inhibitors.
Positive_regulation (caused) of Gene_expression (synthesis) of cGMP in DRG associated with ganglion cysts, dorsal root ganglion, qutenza and bradykinin
8) Confidence 0.05 Published 2001 Journal Nitric Oxide Section Abstract Doc Link 11292360 Disease Relevance 0.36 Pain Relevance 0.30
Evidence that nitric oxide-induced synthesis of cGMP occurs in a paracrine but not an autocrine fashion and that the site of its release can be regulated: studies in dorsal root ganglia in vivo and in vitro.
Positive_regulation (induced) of Gene_expression (synthesis) of cGMP in dorsal root ganglia associated with qutenza
9) Confidence 0.05 Published 2001 Journal Nitric Oxide Section Title Doc Link 11292360 Disease Relevance 0.30 Pain Relevance 0.34
Also, the PDE inhibitor sildenafil increases cytosolic cGMP producing peripheral analgesia via activation of the NO/cGMP/PKG pathway [41].
Positive_regulation (increases) of Gene_expression (producing) of cGMP associated with analgesia
10) Confidence 0.03 Published 2009 Journal Mol Pain Section Body Doc Link PMC2673211 Disease Relevance 0.25 Pain Relevance 0.23

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox